Data-driven drug discovery for targeted medicine
Apricot BIO, a spin-off from the University of Zürich, is positioning itself to become the “Google maps” of the tumor cell by combining drug perturbations, image-based phenotypic profiling, systems biology approaches, and robust predictive modelling. One of the biggest challenges in personalized cancer treatment is that currently only a small proportion of patients are eligible for a targeting-therapy drug. Further, among those treated, most cancer patients are either inherently resistant or eventually acquire resistant to such therapies. By using a novel technological platform that directly measures drug activity in patient`s tumor cells, APx`s goal is to provide evidence-based drug recommendations to clinicians. Thus, providing wider access to personalized therapy.
